Dexa Medica Group registers completed Phase 3 trial of DLBS3233 in prediabetes
The study enrolled 120 participants and was first posted on ClinicalTrials.gov on November 16, 2026. It compared DLBS3233 at 100 mg and 200 mg once daily to Metformin XR 500 mg twice daily over a 12-week course of therapy.
Primary source
ClinicalTrials.gov registry record, November 16, 2026
The Efficacy and Safety of DLBS3233 in Adults With Prediabetes
Read the source: The Efficacy and Safety of DLBS3233 in Adults With Prediabetes clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation